SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
392.00    2.00 (0.51%)
Bid:
385.00
Ask:
399.00
Spread: 14.00 (3.636%)
Market Cap: £188.15m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Peer-reviewed published article

18 Oct 2013 07:00

RNS Number : 8024Q
Tristel PLC
18 October 2013
Β 

ο»Ώ

Tristel plc

("Tristel" or "the Company")

Β 

Peer-reviewed published article supporting Tristel's technology and products

Β 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces the publication of an article in a peer-reviewed journal that describes the benefits of Tristel products.

Β 

The study is titled "A randomised single-blind comparison of the effectiveness of the high-level disinfectants Tristel Fuse (chlorine dioxide) and Cidex OPA (ortho-phthaldehyde) for use with flexible cystoscopes". It has been published in The British Journal of Urology International (on line 10.1111 BJU 12208) and will be published within the Urological Society of Australia and New Zealand (special issue volume 112).

Β 

The article compares the effectiveness, safety and cost of Tristel's chlorine dioxide Fuse chemistry with Cidex OPA (Johnson & Johnson, USA), in an automated endoscope reprocessor (Medivators Inc, USA) for high level disinfection of flexible cystoscopes.

Β 

Tristel Fuse, which was used within the Company's Stella decontamination system, was found to be as effective, more economic and easier for the nursing staff to use than the American products with which it was compared.

Β 

Tristel CEO, Paul Swinney, commented: "This study was initiated in 2009 by the Department of Urology, Tauranga Hospital, New Zealand, and the initial results were reported at the Societe Internationale d'Urologie congress, Shanghai, 2011.

Β 

"This is the first published study that compares our Tristel Fuse and Stella system with one of the world's leading combinations of disinfectant and endoscope washing machine. It demonstrates that our chlorine dioxide technology is just as safe and effective as the world's most widely used medical instrument disinfectant, whilst producing cost savings for hospitals.

Β 

"This study joins the growing body of published scientific evidence demonstrating that Tristel products are superior to the incumbent technologies still being used around the world."

Β 

For further information please contact:

Β 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780

Paul McManus

Mob: 07980 541 893 or paul.mcmanus@walbrookpr.com

Lianne Cawthorne

Mob: 07854 391 303 or lianne.cawthorne@walbrookpr.com

finnCap

Tel: 020 7600 1658

Geoff Nash (Corporate Finance)

Charlotte Stranner (Corporate Finance)

Simon Starr (Corporate Broking)

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
NRANKODPPBDDDKD
Date   Source Headline
1st Jul 20107:00 amRNSDirector/PDMR Shareholding
28th Jun 201010:52 amRNSDirector/PDMR Shareholding
8th Jun 20104:01 pmRNSDirector/PDMR Shareholding
7th Jun 20105:15 pmRNSDirector/PDMR Shareholding
2nd Jun 20103:23 pmRNSDirector/PDMR Shareholding
2nd Jun 20107:00 amRNSDirectorate Change
19th Mar 20107:00 amRNSDirector/PDMR Shareholding
8th Mar 20107:00 amRNSHalf Yearly Report
25th Feb 20107:00 amRNSChange of Adviser
15th Dec 200912:03 pmRNSAGM Statement
4th Dec 20097:00 amRNSDirector/PDMR Shareholding
25th Nov 200910:35 amRNSGeneral Meeting
9th Nov 20097:00 amRNSPlacing and Notice of General Meeting
28th Oct 20099:14 amRNSDividend
13th Oct 20098:35 amRNSGrant of options
12th Oct 20097:00 amRNSFinal Results
18th Sep 20097:00 amRNSLicensing agreement
3rd Jul 200911:28 amRNSDirectors' Dealing
3rd Jul 20097:00 amRNSAcquisition and Placing
11th May 20097:00 amRNSExclusive UK distribution agreement
17th Mar 20099:35 amRNSCorrection to Record Date
16th Mar 20097:00 amRNSHalf Yearly Report
9th Mar 20097:00 amRNSNew infection control range for dental practices
8th Jan 20097:00 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSAGM Statement
7th Nov 20087:00 amRNSNHS Supply Chain listing
6th Oct 20087:00 amRNSFinal Results
3rd Sep 20089:05 amRNSGrant of Patent
25th Jul 20087:00 amRNSTrading update & Notice of re
7th Jul 200810:55 amRNSDirector/PDMR Shareholding
1st Jul 20087:00 amRNSGrant of Patent
23rd Jun 20087:00 amRNSSupply and Distribution Agree
28th May 200811:32 amRNSDirector/PDMR Shareholding
2nd May 20087:00 amRNSDirector/PDMR Shareholding
4th Apr 20085:04 pmRNSCorrection -Board Appointment
4th Apr 20087:01 amRNSDirector/PDMR Shareholding
3rd Apr 20087:00 amRNSBoard Appointment
27th Mar 20089:26 amRNSDirector/PDMR Shareholding
12th Mar 20081:30 pmRNSIssue of Equity
3rd Mar 20087:01 amRNSNew supply agreement
3rd Mar 20087:00 amRNSInterim Results
7th Feb 20087:00 amRNSNotice of Results
6th Feb 20081:19 pmRNSRe. Tristel Italia srl
3rd Jan 20083:29 pmRNSGrant of patent
11th Dec 200711:42 amRNSAGM Statement
5th Nov 200712:38 pmRNSDirector/PDMR Shareholding
29th Oct 20071:01 pmRNSDividend
29th Oct 20077:01 amRNSFinal Results
16th Oct 20077:00 amRNSChange of Adviser
8th Oct 20077:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.